Guillain‐Barré Syndrome After COVID‐19 mRNA Vaccination in a Liver Transplantation Recipient With Favorable Treatment Response

Hughes, Dempsey L; Brunn, Jenna A.; Jacobs, J P A M; Todd, Peter K.; Askari, F. K.; Fontana, Robert J.

doi:10.1002/lt.26279

Cited by 25 publications

(24 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guillain-Barré syndrome has also been associated with mRNA vaccines in a few people. 11 12 In addition, Bell’s palsy, encephalomyelitis, and transverse myelitis events have been described in case series studies after covid-19 vaccination with both viral vector and mRNA vaccines. 13 14 15 16 17 Although these events are not necessarily due to covid-19 vaccines, the temporal association between the events and vaccination warrants robust post-vaccination surveillance.…”

Section: Introductionmentioning

confidence: 99%

“…Owing to reports of people developing Guillain-Barré syndrome after vaccination with Ad.26.COV2.S (108 of 21 million people vaccinated as of late June 2021),8 and ChAdOx1 nCoV-19 (833 people of 592 million doses administered as of late July 2021),910 the EMA listed Guillain-Barré syndrome as a rare side effect related to these vaccines. Guillain-Barré syndrome has also been associated with mRNA vaccines in a few people 1112. In addition, Bell’s palsy, encephalomyelitis, and transverse myelitis events have been described in case series studies after covid-19 vaccination with both viral vector and mRNA vaccines 1314151617.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis

Raventós

Roel

et al. 2022

BMJ

View full text Add to dashboard Cite

Objective To study the association between covid-19 vaccines, SARS-CoV-2 infection, and risk of immune mediated neurological events. Design Population based historical rate comparison study and self-controlled case series analysis. Setting Primary care records from the United Kingdom, and primary care records from Spain linked to hospital data. Participants 8 330 497 people who received at least one dose of covid-19 vaccines ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, or Ad.26.COV2.S between the rollout of the vaccination campaigns and end of data availability (UK: 9 May 2021; Spain: 30 June 2021). The study sample also comprised a cohort of 735 870 unvaccinated individuals with a first positive reverse transcription polymerase chain reaction test result for SARS-CoV-2 from 1 September 2020, and 14 330 080 participants from the general population. Main outcome measures Outcomes were incidence of Bell’s palsy, encephalomyelitis, Guillain-Barré syndrome, and transverse myelitis. Incidence rates were estimated in the 21 days after the first vaccine dose, 90 days after a positive test result for SARS-CoV-2, and between 2017 and 2019 for background rates in the general population cohort. Indirectly standardised incidence ratios were estimated. Adjusted incidence rate ratios were estimated from the self-controlled case series. Results The study included 4 376 535 people who received ChAdOx1 nCoV-19, 3 588 318 who received BNT162b2, 244 913 who received mRNA-1273, and 120 731 who received Ad26.CoV.2; 735 870 people with SARS-CoV-2 infection; and 14 330 080 people from the general population. Overall, post-vaccine rates were consistent with expected (background) rates for Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome. Self-controlled case series was conducted only for Bell’s palsy, given limited statistical power, but with no safety signal seen for those vaccinated. Rates were, however, higher than expected after SARS-CoV-2 infection. For example, in the data from the UK, the standardised incidence ratio for Bell’s palsy was 1.33 (1.02 to 1.74), for encephalomyelitis was 6.89 (3.82 to 12.44), and for Guillain-Barré syndrome was 3.53 (1.83 to 6.77). Transverse myelitis was rare (<5 events in all vaccinated cohorts) and could not be analysed. Conclusions No safety signal was observed between covid-19 vaccines and the immune mediated neurological events of Bell’s palsy, encephalomyelitis, Guillain-Barré syndrome, and transverse myelitis. An increased risk of Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome was, however, observed for people with SARS-CoV-2 infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis

Raventós

Roel

et al. 2022

BMJ

View full text Add to dashboard Cite

show abstract

“…Thirty-four articles, comprising 57 patients, were included in this study [ 4 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ]. The search and selection process are detailed in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Prognosis of Guillain–Barré Syndrome Linked to COVID-19 Vaccination

et al. 2022

View full text Add to dashboard Cite

There have been increasing reports of Guillain–Barré syndrome (GBS), a rare but debilitating neurological disease, occurring post-COVID-19 vaccination. However, the outcomes and relationships between patient demographics and clinical outcomes of post-COVID-19 vaccination GBS remain unclear. To bridge this gap, our study investigates the outcomes and clinical factors associated with poorer GBS outcomes following COVID-19 vaccination. We conducted a review and pooled analysis of detailed data extracted from 57 published cases with the relevant search strategies and criteria. The groups compared included male versus female patients, 1st dose versus 2nd dose and early onset versus late onset of GBS. Multivariate regression analysis was performed to compare the vaccine type, clinical severity and post-treatment outcomes between these groups of patients. Our results highlight for the first time that females were significantly more likely to have severe clinical presentation and poorer outcomes compared to males. Additionally, viral vector vaccines were the predominant vaccine type administered in early-onset post-COVID-19-vaccination GBS and GBS occurring after the 1st vaccination dose. It was also shown that reported cases of post-vaccination GBS generally displayed a positive response to conventional treatment and had favourable post-treatment outcomes. Through this study, we have established important links and provided assuring evidence for treatment response and post-treatment outcomes of GBS occurring post-COVID-19 vaccination. While the COVID-19 vaccination brings about much greater benefits than risks, our findings provide further impetus for greater vigilance in certain patient groups and more studies to explore the mechanisms behind these links.

show abstract

“…Table 1 shows a PUBMED literature review of reported incidences of GBS after COVID-19 vaccination with various vaccine types given across the world [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] . We included CDC and WHO analyses of larger population groups.…”

Section: Discussionmentioning

confidence: 99%

Vaccine hesitancy with a history of Guillain Barre Syndrome: Weighing the risks and benefits of SARS-CoV-2 vaccination

Baptista

Alok

Libertin

2022

IDCases

View full text Add to dashboard Cite

Guillain‐Barré Syndrome After COVID‐19 mRNA Vaccination in a Liver Transplantation Recipient With Favorable Treatment Response

Cited by 25 publications

References 8 publications

Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis

Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis

Prognosis of Guillain–Barré Syndrome Linked to COVID-19 Vaccination

Vaccine hesitancy with a history of Guillain Barre Syndrome: Weighing the risks and benefits of SARS-CoV-2 vaccination

Contact Info

Product

Resources

About